The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000709347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
12/05/2026
Date registered
Help: Date registered
12/06/2026
Date last updated
Help: Date last updated
12/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
12/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
C-IMPACT: A phase 1 PET-CT study to evaluate the safety, biodistribution and pharmacokinetics of 89Zrhu/mo-10D7 in locally advanced or distant metastatic CDCP1 positive epithelial cancers
Scientific title
C-IMPACT: A phase 1 PET-CT study to evaluate the safety, biodistribution and pharmacokinetics of 89Zrhu/mo-10D7 in locally advanced or distant metastatic CDCP1 positive epithelial cancers
Additional trial identifiers [1] 317269 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Ovarian Cancer 341893 0
Bladder Cancer 341894 0
Breast Cancer 341895 0
Pancreatic Cancer 341896 0
Condition category
Condition code
Cancer 337952 337952 0 0
Bladder
Cancer 337953 337953 0 0
Breast
Cancer 337954 337954 0 0
Pancreatic
Cancer 337955 337955 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive a single dose of hu/mo-10D7 as an intravenous infusion over 30 minutes to deliver a maximum dose of 90 ug/Kg. Hu/mo-10D7 will be a mixture of un-labelled and labelled protein, in solution, with a total of 37 MBq of 89Zr-labelled antibody.
The principle invesitgator at nuclear medicine will administer the imaging agent.
Patients will undergo PET/CT scans at screening and full body PET scans at imaging visits
This study consists of the following hospital visits:
• Screening (up to 30 days prior to injection of the imaging agent)
• Day 0: Injection of the imaging agent, imaging, and assessments
• Day 1: PET Imaging and assessments including vitals and bloods approx 4hrs
• Day 3: Imaging and assessments including vitals and bloods approx 2hrs
• Day 7: Imaging and assessments including vitals and bloods approx 2hrs
Intervention code [1] 334039 0
Diagnosis / Prognosis
Description of the comparator or control
No Control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345387 0
Determine the safety of 89Zr-hu/mo-10D7 in patients who have a locally advanced or metastatic epithelial cancer that is CDCP1 positive.
Timepoint [1] 345387 0
Screening (Day -28 to Day -1) Day 0 - Baseline and Intervention. Baseline assessments will be performed before Imaging agent administered. Vital timepoints will be conducted at 30mins, 1h, 2h and 4hr post imaging agent ECG at 2hr post imaging agent Day 2 (± 1 d) Bloods (PK & radioactive), vitals, AE review, imaging Day 5 (± 1 d) Bloods (FBC, PK,Radioactive) urine, imaging Day 7 (± 1 d) If not completed at Day 5 Bloods (PK & radioactive), vitals, AE review, imaging
Secondary outcome [1] 461487 0
Demonstrate evidence of 89Zr-hu/mo-10D7 localisation to tumour sites.
Timepoint [1] 461487 0
Screening (Day -28 to Day -1) Day 0 - Baseline assessments to be completed prior to imaging agent injection, Day 0 Intervention, post-injection PET scan and assessments Day 2 (± 1 d) PET scan and assesments Day 5 (± 1 d) PET scan and assesments Day 7 (± 1 d) If not completed at Day 5 PET scan and assesments *A minimum of 1 and a maximum of 4 imaging timepoints will be undertaken.
Secondary outcome [2] 461991 0
Determine the pharmacokinetics and biodistribution of 89Zrhu/mo-10D7
Timepoint [2] 461991 0
PK bloods will be taken at Day 0 predose, 1hr, 2hr, 4hr post dose Day 2 Day 5 Day 7
Secondary outcome [3] 461992 0
Perform dosimetry estimates for tumours to determine if there is a suitable therapeutic window.
Timepoint [3] 461992 0
Day 0 immediately post injection, Day 2, Day 5 and Day 7 post injection
Secondary outcome [4] 462676 0
Perform dosimetry estimates normal organs
Timepoint [4] 462676 0
Day 0 immediately post injection, Day 2, Day 5 and Day 7 post injection

Eligibility
Key inclusion criteria
Provide a signed and dated informed consent form
Be willing to comply with all study procedures and be available for the duration of the
study
Adults 18 years and above
Have histologically confirmed epithelial cancer
Visible locally advanced or metastatic disease on conventional cross-sectional imaging
(for example diagnostic contrast CT and/or FDG-PET imaging)
CDCP1 expression greater than 100 proven on tumour sample by immunohistochemistry
ECOG performance status of 0-1
Expected survival more than 3 months
Women of reproductive potential must use highly effective contraception and abstain from getting pregnant during the trial period
Adequate organ function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
History of major immunologic reaction to any IgG containing agent
Prior or ongoing clinically significant illness, medical condition(s), surgical history,
physical finding, electrocardiogram (ECG) finding, or laboratory abnormality that, in the investigator’s opinion, could place the patient at an unacceptably high risk, adversely affect the safety of the patient or impair the assessment of study results
Patient is pregnant, lactating, and/or plans to become pregnant within the trial period
Exposure within the past 5 years to chimeric or murine antibodies
Exposure to a radiopharmaceuticals within the washout period (washout 10 half-lives of the radionuclide)

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29516 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [2] 29517 0
Mater Hospital Brisbane - South Brisbane
Recruitment postcode(s) [1] 45833 0
4029 - Herston
Recruitment postcode(s) [2] 45834 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 321842 0
Charities/Societies/Foundations
Name [1] 321842 0
Pankind Funding
Country [1] 321842 0
Australia
Funding source category [2] 321843 0
University
Name [2] 321843 0
University of Queensland
Country [2] 321843 0
Australia
Funding source category [3] 321844 0
Government body
Name [3] 321844 0
Health and Medical Research Office (HMRO) (MRFF grant)
Country [3] 321844 0
Australia
Funding source category [4] 321845 0
Commercial sector/Industry
Name [4] 321845 0
Brandon Capital
Country [4] 321845 0
Australia
Primary sponsor type
Hospital
Name
Mater Hospital
Address
Country
Australia
Secondary sponsor category [1] 324698 0
None
Name [1] 324698 0
Address [1] 324698 0
Country [1] 324698 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320383 0
Mater Misericordiae Ltd Human Research Ethics Committee
Ethics committee address [1] 320383 0
Ethics committee country [1] 320383 0
Australia
Date submitted for ethics approval [1] 320383 0
07/04/2026
Approval date [1] 320383 0
Ethics approval number [1] 320383 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150302 0
Prof Roslyn Francis
Address 150302 0
288 Herston Rd,Level 3, Ned Hanlon Building Royal Brisbane & Women's Hospital Herston, QLD 4006
Country 150302 0
Australia
Phone 150302 0
+61 73646 7593
Fax 150302 0
Email 150302 0
Contact person for public queries
Name 150303 0
Bronwyn Alchin
Address 150303 0
Medical Research Mater Misericordiae Ltd Room 257, Level 2 Aubigny Place Raymond Tce, South Brisbane, Qld 4101
Country 150303 0
Australia
Phone 150303 0
+61 407130567
Fax 150303 0
Email 150303 0
Contact person for scientific queries
Name 150304 0
John Hooper
Address 150304 0
Translational Research Institute | Level 4, Office 4078, 37 Kent Street, Woolloongabba, QLD 4102, AUSTRALIA
Country 150304 0
Australia
Phone 150304 0
+61 411065634
Fax 150304 0
Email 150304 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Patients can contact the Mater Hospital, Medical Research email [email protected] to request information.

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.